New antibody combo aims to keep bone cancer at bay
NCT ID NCT02502786
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This phase II trial tests a humanized antibody called Hu3F8 combined with GM-CSF (a drug that boosts the immune system) in children and young adults with recurrent osteosarcoma, a type of bone cancer. The goal is to see if this treatment can extend the time before the cancer returns or prevent relapse altogether. The study enrolls 46 participants who are already in remission after a recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- humanized antibody 3F8 (Hu3F8) and GM-CSF
- What this could lead to
- If it works, this could help keep recurrent osteosarcoma in remission longer and delay or prevent the cancer from coming back.
- What could go wrong
- This is a small, early-phase trial (46 participants) with no control group, so results may not be conclusive. The treatment may cause side effects and might not prevent relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Los Angeles (Data Collection Only)
Los Angeles, California, 90027, United States
-
MD ANDERSON CANCER CENTER (Data Collection Only)
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Desperate hope: single patient gets custom RNA therapy for returning bone cancer
- Targeted drug shows promise for kids with tough cancers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- New drug targets tough childhood cancers with genetic flaws
- Experimental drug shows promise for Tough-to-Treat bone cancers
- New hope for young cancer patients: experimental drug targets recurrent tumors